<style face="normal" font="default" size="100%">711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials</style>

Drupal-HighWire